Eli Lilly (LLY) PT Raised to $250 at Mizuho Securities as Donanemab Granted Breakthrough Therapy Designation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Eli Lilly (LLY) PT Raised to 'Street High' $300 at Cantor Fitzgerald
June 24, 2021 9:10 AM EDTCantor Fitzgerald analyst Louise Chen raised the price target on Eli Lilly (NYSE: LLY) to a "Street High" $300.00 (from $245.00) while maintaining an Overweight rating after the FDA has granted its Alzheimer's disease drug donanemab Breakthrough Therapy Designation.
... MoreEli Lilly (LLY) PT Raised to $250 at Cowen
June 24, 2021 8:16 AM EDTCowen analyst Steve Scala raised the price target on Eli Lilly (NYSE: LLY) to $250.00 (from $235.00) while maintaining an Outperform rating.
The analyst commented, "Earlier this week, FDA released internal memos on regulatory decisions regarding BIIB's aducanumab for AD. Our KOLs conclude they strengthen donanemab... More
Eli Lilly & Co. (LLY) option implied volatility into receives therapy designation for donanemab from FDA
June 24, 2021 7:24 AM EDTEli Lilly & Co. (NYSE: LLY) 30-day option implied volatility is at 23; compared to its 52-week range of 22 to 46 into receives therapy designation for donanemab from FDA.
... MoreStocks expected to have increasing option volume: LLY SCS DRI RAD
June 24, 2021 7:20 AM EDTStocks expected to have increasing option volume: LLY SCS DRI RAD
... MoreBiogen (BIIB) declines 3.5% after Lilly's (LLY) donanemab receives FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
June 24, 2021 7:11 AM EDTBiogen (NASDAQ: BIIB) declines 3.5% after Lilly's (NYSE: LLY) donanemab receives FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
Lilly shares were up 8.3%... MoreLilly's (LLY) donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
June 24, 2021 6:46 AM EDTThe U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's (NYSE: LLY) investigational antibody therapy for Alzheimer's disease (AD). The Breakthrough Therapy designation aims to expedite the development and review of drugs that are intended to treat a serious condition when... More
